Research programme: anthracyclines - Galilaeus OyAlternative Names: Research programme: anticancer therapeutics - Galilaeus Oy/Heidelberg Pharma; S 2512; S 2513
Latest Information Update: 16 Nov 2010
At a glance
- Originator Galilaeus Oy
- Developer Heidelberg Pharma
- Class Anthracyclines
- Mechanism of Action DNA inhibitors; RNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 May 2003 Preclinical trials in Cancer in Finland (unspecified route)
- 15 May 2003 S 2513 and S 2521 are available for licensing (http://www.galilaeus.fi)